Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Kinnate Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO – August 8, 2023 –"
05/11/2023 8-K Quarterly results
Docs: "Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates"
03/15/2023 8-K Quarterly results
Docs: "Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – November 10, 2021 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended September 30, 2021."
08/16/2021 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – August 16, 2021 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021. The company also announced that the first patient has commenced treatment in its Phase 1 KN-8701 clinical trial evaluating its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma and other solid tumors."
05/17/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy